Flash Finance

Bajaj Healthcare LimitedBAJAJHCARECorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹341.10
MCap ₹1,148 Cr · P/E 63.3
Bajaj Healthcare Limited — Stock analysis & AI research Bajaj Healthcare Limited — Multibagger AI analysis Bajaj Healthcare Limited — Seasonality — best & worst months Bajaj Healthcare Limited — Technical setup — score, trend, support & resistance Bajaj Healthcare Limited — Live exchange announcements
📈 MACD Bullish Crossover📈 Stocks Above Anchored VWAP 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹166 Cr
Sales · Jun 2026
+11.4% YoY
₹29 Cr
Operating Profit · Jun 2026
+16.0% YoY
17.5%
OPM % · Jun 2026
+4.2% YoY
₹14 Cr
Net Profit · Jun 2026
+16.7% YoY
₹4.07
EPS · Jun 2026
+8.5% YoY

📝 Bajaj Healthcare Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Bajaj Healthcare Limited reported revenue of ₹166 crore for the quarter ended June 2026 (Q1 FY27), up 11.4% from ₹149 crore in the same quarter last year, and up 8.5% sequentially over the March 2026 quarter.

Net profit rose 16.7% year-on-year to ₹14 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹4.07.

Operating profit stood at ₹29 crore — an operating margin (OPM) of 17.5%, compared with 16.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Bajaj Healthcare Limited posted revenue of ₹611 crore, a growth of 12.7% over FY25, with a net profit of ₹16 crore (down 59.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹628 crore with a net profit of ₹18 crore.

Valuation snapshot

At the current price of ₹341.10, BAJAJHCARE has a market capitalisation of ₹1,148 crore and a trailing P/E of about 63.3.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 58.29%, foreign institutional investors (FIIs) 1.98%, domestic institutional investors (DIIs) 2.91%, public shareholders 36.82% of Bajaj Healthcare Limited.

Promoter holding slipped from 59.19% to 58.29% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,148 Cr
Current Price ?
₹341.1
P/E ?
63.27above ind
Industry P/E ?
37.20
P/B ?
2.15
P/S ?
1.83
P/FCF ?
63.80
Enterprise Value ?
₹1,397 Cr
EV/EBITDA ?
12.74
PEG ?
21.09
Earnings Yield ?
5.8%
Dividend Yield ?
0.29%
Profitability & Returns
Sales (TTM) ?
₹628 Cr
OPM ?
17.5%
Profit after tax (TTM) ?
₹18 Cr
EPS (TTM) ?
₹5.39
ROCE ?
11.0%
ROE ?
3.4%
ROA ?
2.0%
Growth
Sales — latest qtr ?
₹166 Cr
PAT — latest qtr ?
₹14 Cr
YoY qtr sales growth ?
11.4%
YoY qtr profit growth ?
16.7%
Sales growth (3y) ?
-2%
Sales growth (5y) ?
-1%
Profit growth (3y) ?
3%
Profit growth (5y) ?
-11%
Financial Health
Debt ?
₹249 Cr
Debt to Equity ?
0.47
Interest Coverage ?
3.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
58.29%
Change in promoter holding ?
-0.90%
Pledged percentage ?
N/A
Market
Return 3 months ?
-8.8%
Return 6 months ?
-2.4%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 154130101109134132133123154149148161153166 +11.4% +8.5%
Operating Profit 2222192016242522122527312329 +16.0% +27.9%
Other Income -7-55-7-7-3603-11310131 +0.0% -66.2%
Interest 239876886656666 +20.0% +7.8%
Depreciation 276777777867787 +16.7% -8.2%
Profit Before Tax 58-48-3-1-33912811141519-2116 +14.3% +176.9%
Net Profit 4-48-3-2-30791211121116-2314 +16.7% +161.3%
EPS 1.30-17.47-1.25-0.80-10.842.583.363.713.543.753.524.96-7.164.07 +8.5% +156.8%
OPM % 14.3% 16.9% 18.8% 18.3% 11.9% 18.2% 18.4% 17.9% 7.8% 16.8% 18.2% 19.3% 14.8% 17.5% +4.2% +18.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹542 Cr ₹611 Cr ₹628 Cr +12.7%
Operating Profit ₹83 Cr ₹106 Cr ₹110 Cr +28.1%
OPM % 15.22% 17.29% 17.46% +13.6%
NPM % 7.28% 2.64% 2.89% -63.7%
Other Income ₹15 Cr ₹5 Cr ₹5 Cr -66.1%
Depreciation ₹29 Cr ₹28 Cr ₹29 Cr -4.1%
Interest ₹28 Cr ₹23 Cr ₹24 Cr -19.0%
EBIT ₹54 Cr ₹78 Cr ₹81 Cr +45.3%
PBT ₹40 Cr ₹27 Cr ₹29 Cr -32.8%
Tax ₹4 Cr ₹-1 Cr ₹1 Cr -134.0%
Net Profit ₹39 Cr ₹16 Cr ₹18 Cr -59.1%
EPS ₹13.19 ₹5.07 ₹5.39 -61.6%
Material Cost ₹55 Cr ₹92 Cr ₹184 Cr +67.4%
Employee Cost ₹14 Cr ₹16 Cr ₹34 Cr +16.5%
Extraordinary Items — ₹-33 Cr ₹-33 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 14141617 +6.2%
Reserves 354265450516 +14.7%
Borrowings 415333223249 +11.7%
Other Liabilities 115154144141 -2.1%
Total Liabilities 898765833923 +10.8%
Fixed Assets 366253238248 +4.2%
CWIP 22738 +166.7%
Investments 0000 —
Other Assets 510506591667 +12.9%
Total Assets 898765833923 +10.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -22922258 +163.6%
Cash from Investing Activity -93-11-15-48 -220.0%
Cash from Financing Activity 131-97-624 +500.0%
Net Cash Flow 16-16035 —
Free Cash Flow -115731018 +80.0%
CFO/OP -10%138%32%53% +65.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 110139169140 -17.2%
Inventory Days 199206206249 +20.9%
Days Payable 81128122133 +9.0%
Cash Conversion Cycle 228217254256 +0.8%
Working Capital Days 27-0140119 -15.0%
ROCE % 14%8%11%11% +0.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 59.19%59.19%59.19%58.29% -1.5%
FIIs 1.09%1.12%1.18%1.98% +67.8%
DIIs 3.16%2.99%2.96%2.91% -1.7%
Public 36.56%36.70%36.67%36.82% +0.4%
No. of Shareholders 35,98038,57637,95338,158 +0.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 BAJAJHCARE Bajaj Healthcare ₹327.00 1,101 60.7 628 18 17.5% 2.9% 12.7% -59.1% 11.4% 16.7%
❓ Frequently asked questions
What was Bajaj Healthcare Limited's revenue in Q1 FY27?
Bajaj Healthcare Limited reported revenue of ₹166 crore for the quarter ended June 2026 (Q1 FY27), up 11.4% from ₹149 crore in the same quarter last year, and up 8.5% sequentially over the March 2026 quarter.
What was Bajaj Healthcare Limited's net profit in Q1 FY27?
Net profit rose 16.7% year-on-year to ₹14 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹4.07.
What is BAJAJHCARE's market capitalisation and P/E ratio?
At the current price of ₹341.10, BAJAJHCARE has a market capitalisation of ₹1,148 crore and a trailing P/E of about 63.3.
Who owns Bajaj Healthcare Limited? (shareholding pattern)
As of Mar 2026, promoters held 58.29%, foreign institutional investors (FIIs) 1.98%, domestic institutional investors (DIIs) 2.91%, public shareholders 36.82% of Bajaj Healthcare Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI